https://www.biopharmawatch.com/news/AXGN/axogen-acquires-biocircuit-nervetape-device BiopharmaWatch en 2026-10-01T21:19:00.000Z Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T21:10:00.000Z Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T21:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HYFT/mindwalk-nomme-kim-remizowski-au-conseil-d-apos-administration-titre BiopharmaWatch en 2026-10-01T20:50:00.000Z MindWalk nomme Kim Remizowski au conseil d'administration à titre d'administrateur indépendant https://www.biopharmawatch.com/news/ELUT/elutia-boston-scientific-payment-2026 BiopharmaWatch en 2026-10-01T20:45:00.000Z Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-underwritten-offering-2026 BiopharmaWatch en 2026-10-01T20:31:00.000Z Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:30:29.000Z X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/EHC/encompass-health-2026-q3-earnings-call BiopharmaWatch en 2026-10-01T20:30:00.000Z Encompass Health announces date of 2026 third-quarter earnings call https://www.biopharmawatch.com/news/EW/edwards-lifesciences-fda-approval-autus-valve BiopharmaWatch en 2026-10-01T20:26:00.000Z Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients https://www.biopharmawatch.com/news/ADRX/adarx-pharmaceuticals-ipo-shares-exercise BiopharmaWatch en 2026-10-01T20:15:00.000Z ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering https://www.biopharmawatch.com/news/NBTX/nanobiotix-appoints-arnd-christ-cfo BiopharmaWatch en 2026-10-01T20:15:00.000Z NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer https://www.biopharmawatch.com/news/STLN/starling-oncology-industry-conference-participation BiopharmaWatch en 2026-10-01T20:14:00.000Z Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation https://www.biopharmawatch.com/news/ABCL/abcellera-q3-2026-financial-results BiopharmaWatch en 2026-10-01T20:05:00.000Z AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2026-results-announcement BiopharmaWatch en 2026-10-01T20:05:00.000Z Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/CNMD/conmed-corporation-third-quarter-2026-results BiopharmaWatch en 2026-10-01T20:05:00.000Z CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-presentation-aha-2026 BiopharmaWatch en 2026-10-01T20:05:00.000Z Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/RMD/resmed-report-first-quarter-fiscal-2027-earnings BiopharmaWatch en 2026-10-01T20:05:00.000Z Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-inducement-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-10-01T20:05:00.000Z Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-cpt-codes-approval BiopharmaWatch en 2026-10-01T20:03:00.000Z Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel https://www.biopharmawatch.com/news/REPL/tudriqev-available-us-advanced-melanoma BiopharmaWatch en 2026-10-01T20:01:00.000Z Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-arv-102-parkinsons-congress-2026 BiopharmaWatch en 2026-10-01T20:01:00.000Z Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® https://www.biopharmawatch.com/news/MDT/medtronic-cpt-code-approvals-altaviva-symplicity-spyral BiopharmaWatch en 2026-10-01T20:00:00.000Z Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems https://www.biopharmawatch.com/news/MGRX/mangoceuticals-secures-strategic-investment-in-mangorx-ip BiopharmaWatch en 2026-10-01T19:50:00.000Z Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche https://www.biopharmawatch.com/news/SYK/stryker-syk-peripheral-vascular-issues-investigation BiopharmaWatch en 2026-10-01T18:21:00.000Z Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-q3-2026-financial-results BiopharmaWatch en 2026-10-01T15:30:00.000Z IDEXX Laboratories to Release 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/ABBV/abbvie-rinvoq-repigmentation-non-segmental-vitiligo BiopharmaWatch en 2026-10-01T14:06:19.906Z AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo https://www.biopharmawatch.com/news/CDRE/lilysilk-renews-partnership-nbcf-a-bloom-of-care BiopharmaWatch en 2026-10-01T14:00:00.000Z Cinq ans de mode engagée : LILYSILK renouvelle son partenariat avec la National Breast Cancer Foundation dans le cadre de la campagne « A Bloom of Care » https://www.biopharmawatch.com/news/STVN/ensera-alliance-network-launch-partnerships BiopharmaWatch en 2026-10-01T13:32:00.000Z Ensera lance un réseau de partenariat avec SHL Medical, Stevanato Group, Ypsomed, Argonaut et American Injectables https://www.biopharmawatch.com/news/STVN/ensera-alliance-network-launch BiopharmaWatch en 2026-10-01T13:32:00.000Z Ensera startet Allianz-Netzwerk mit SHL Medical, der Stevanato Group, Ypsomed, Argonaut und American Injectables https://www.biopharmawatch.com/news/GANX/gain-therapeutics-rexaceract-phase-1b-data BiopharmaWatch en 2026-10-01T13:28:00.000Z Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-dr-robert-spiegel-appointment BiopharmaWatch en 2026-10-01T13:20:00.000Z Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic https://www.biopharmawatch.com/news/PYPD/eu-ema-validates-polypids-marketing-authorization-application BiopharmaWatch en 2026-10-01T13:15:00.000Z European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ https://www.biopharmawatch.com/news/BCDA/biocardia-revised-de-novo-pre-submission-fda-helix-catheter BiopharmaWatch en 2026-10-01T13:15:00.000Z BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-strategy BiopharmaWatch en 2026-10-01T13:02:00.000Z AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-submits-hcpcs-application-lytenava BiopharmaWatch en 2026-10-01T13:01:00.000Z Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) https://www.biopharmawatch.com/news/NVCR/novocure-optune-pax-approval-japan-pancreatic-cancer BiopharmaWatch en 2026-10-01T13:00:00.000Z Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/WAT/waters-corporation-q3-2026-earnings-call BiopharmaWatch en 2026-10-01T13:00:00.000Z Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/LEGN/legend-biotech-launches-elite-grant-program BiopharmaWatch en 2026-10-01T13:00:00.000Z Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma https://www.biopharmawatch.com/news/CARL/carlsmed-appoints-tony-jarc-chief-product-ai-officer BiopharmaWatch en 2026-10-01T13:00:00.000Z Carlsmed Appoints Tony Jarc as Chief Product and AI Officer https://www.biopharmawatch.com/news/CHE/chemed-third-quarter-2026-earnings-report BiopharmaWatch en 2026-10-01T13:00:00.000Z Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28 https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-lx2006-presentation-mds-2026 BiopharmaWatch en 2026-10-01T13:00:00.000Z Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) https://www.biopharmawatch.com/news/PYPD/polypid-regains-european-rights-d-plex1800 BiopharmaWatch en 2026-10-01T12:56:00.000Z PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities https://www.biopharmawatch.com/news/DGX/haystack-mrd-demonstrates-clinical-performance-dynamic-trials BiopharmaWatch en 2026-10-01T12:52:00.000Z Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials https://www.biopharmawatch.com/news/HYFT/mindwalk-appoints-kim-remizowski-independent-director BiopharmaWatch en 2026-10-01T12:46:00.000Z MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-second-patient-fifth-cohort-ovarian-cancer BiopharmaWatch en 2026-10-01T12:35:00.000Z Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-age-better-campaign-kelly-slater BiopharmaWatch en 2026-10-01T12:32:00.000Z Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater https://www.biopharmawatch.com/news/SABS/sab-bio-present-sab-142-data-breakthrough-t1d-congress BiopharmaWatch en 2026-10-01T12:30:47.000Z SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress https://www.biopharmawatch.com/news/ALGN/align-technology-third-quarter-2026-results BiopharmaWatch en 2026-10-01T12:30:00.000Z Align Technology to Announce Third Quarter 2026 Results on October 28, 2026 https://www.biopharmawatch.com/news/QTI/qt-imaging-cpt-code-3d-breast-imaging BiopharmaWatch en 2026-10-01T12:30:00.000Z QT Imaging Announces CPT® Category III Code for 3D Breast Acoustic Imaging Now Effective https://www.biopharmawatch.com/news/EOLS/evolus-launches-wings-charitable-platform BiopharmaWatch en 2026-10-01T12:30:00.000Z Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes https://www.biopharmawatch.com/news/ACOG/alpha-cognition-converge-real-world-evidence-zunveyl BiopharmaWatch en 2026-10-01T12:30:00.000Z Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-aziz-sawaf-cfo BiopharmaWatch en 2026-10-01T12:30:00.000Z Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-clinical-study-burns BiopharmaWatch en 2026-10-01T12:30:00.000Z Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet https://www.biopharmawatch.com/news/NXL/nexalin-technology-distribution-agreement-brazil-south-america BiopharmaWatch en 2026-10-01T12:30:00.000Z Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-benjamin-halladay-cfo BiopharmaWatch en 2026-10-01T12:30:00.000Z Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer https://www.biopharmawatch.com/news/RNXT/renovorx-peer-reviewed-publication-tamp-platform BiopharmaWatch en 2026-10-01T12:30:00.000Z RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-pct-filing-adc-payload-cancer BiopharmaWatch en 2026-10-01T12:25:00.000Z Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-rezpegaldesleukin-eadv-2026 BiopharmaWatch en 2026-10-01T12:23:00.000Z /C O R R E C T I O N -- Nektar Therapeutics/ https://www.biopharmawatch.com/news/ICU/new-icd-10-pcs-codes-seastar-medical-scd-therapy BiopharmaWatch en 2026-10-01T12:21:00.000Z New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI) https://www.biopharmawatch.com/news/CADL/candel-therapeutics-phase-2a-trial-results-nsclc BiopharmaWatch en 2026-10-01T12:05:00.000Z Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-q3-2026-results BiopharmaWatch en 2026-10-01T12:05:00.000Z BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026 https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-poster-presentation-european-narcolepsy-days BiopharmaWatch en 2026-10-01T12:05:00.000Z Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days https://www.biopharmawatch.com/news/MCK/mckesson-cvs-health-distribution-agreement-extension BiopharmaWatch en 2026-10-01T12:03:00.000Z McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-study-webinar BiopharmaWatch en 2026-10-01T12:03:00.000Z 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar https://www.biopharmawatch.com/news/LABT/lakewood-amedev-biotherapeutics-october-conferences BiopharmaWatch en 2026-10-01T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences https://www.biopharmawatch.com/news/A/agilent-novostation-sample-preparation-system-launch BiopharmaWatch en 2026-10-01T12:00:00.000Z Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows https://www.biopharmawatch.com/news/EVMN/evommune-evo301-phase-2a-atopic-dermatitis-eadv-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress https://www.biopharmawatch.com/news/OGN/organon-real-world-analysis-vtama-fall-conference BiopharmaWatch en 2026-10-01T12:00:00.000Z Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference https://www.biopharmawatch.com/news/BFLY/mendaera-focalist-butterfly-ultrasound-chip-technology BiopharmaWatch en 2026-10-01T12:00:00.000Z Mendaera’s Focalist™ System Now Compatible with Butterfly’s Ultrasound-on-Chip™ Technology https://www.biopharmawatch.com/news/MOH/molina-healthcare-nebraska-lead-testing-donation BiopharmaWatch en 2026-10-01T12:00:00.000Z Molina Healthcare of Nebraska Donates $30,000 to Support Lead Testing in Over 20 Rural Counties https://www.biopharmawatch.com/news/AZTR/azitra-advances-atr-04-phase-1-2-trial-cohort-2 BiopharmaWatch en 2026-10-01T12:00:00.000Z Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-muc16-ovarian-cancer-igcs-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-20261001 BiopharmaWatch en 2026-10-01T12:00:00.000Z Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/ABBV/abbvie-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-01T12:00:00.000Z AbbVie to Host Third-Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/AKTS/aktis-oncology-phase-1b-trial-aky-2519 BiopharmaWatch en 2026-10-01T12:00:00.000Z Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 https://www.biopharmawatch.com/news/DXR/daxor-showcase-next-gen-blood-volume-analyzer-hfsa-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 https://www.biopharmawatch.com/news/SYK/stryker-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-01T12:00:00.000Z Stryker to announce third quarter 2026 financial results https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-backbeat-trial-enrollment-exceeds-target BiopharmaWatch en 2026-10-01T12:00:00.000Z Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-tsha-102-rett-syndrome-presentations BiopharmaWatch en 2026-10-01T12:00:00.000Z Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting https://www.biopharmawatch.com/news/SGP/spyglass-pharma-acquires-advanced-vision-science BiopharmaWatch en 2026-10-01T12:00:00.000Z SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability https://www.biopharmawatch.com/news/MDLN/medline-lanza-la-campana-10-minutos-que-importan-para-destacar BiopharmaWatch en 2026-10-01T11:32:00.000Z Medline lanza la campaña «10 minutos que importan» para destacar el valor del tiempo en el quirófano https://www.biopharmawatch.com/news/NKTR/update-nektar-therapeutics BiopharmaWatch en 2026-10-01T11:30:00.000Z /UPDATE -- Nektar Therapeutics/ https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-eadv-congress-2026 BiopharmaWatch en 2026-10-01T11:30:00.000Z New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 https://www.biopharmawatch.com/news/MDLN/10-minutes-that-make-difference-medline BiopharmaWatch en 2026-10-01T11:30:00.000Z Medline startet die Kampagne „10 Minuten, die den Unterschied machen ", um den Wert der Zeit im Operationssaal hervorzuheben https://www.biopharmawatch.com/news/IFRX/inflarx-appoints-gabriela-alperovich-as-svp-global-head-clinical-development BiopharmaWatch en 2026-10-01T11:30:00.000Z InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development https://www.biopharmawatch.com/news/ABUS/arbutus-final-results-230-million-tender-offer BiopharmaWatch en 2026-10-01T11:30:00.000Z Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/WVE/wave-life-sciences-fda-feedback-wve-006 BiopharmaWatch en 2026-10-01T11:30:00.000Z Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-sjogren-disease-issjd-2026 BiopharmaWatch en 2026-10-01T11:30:00.000Z Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) https://www.biopharmawatch.com/news/HELP/helus-pharma-completes-legal-name-change BiopharmaWatch en 2026-10-01T11:30:00.000Z Helus Pharma Announces Completion of Legal Name Change https://www.biopharmawatch.com/news/MDLN/10-minutes-that-matter-medline-campaign BiopharmaWatch en 2026-10-01T11:29:00.000Z Medline lance la campagne « 10 Minutes That Matter » pour mettre en avant l'importance du temps au bloc opératoire https://www.biopharmawatch.com/news/MDLN/medline-10-minutes-that-matter-campaign BiopharmaWatch en 2026-10-01T11:27:00.000Z Medline launches "10 Minutes That Matter" campaign to spotlight the value of time in the operating theatre https://www.biopharmawatch.com/news/USNA/celebrate-international-music-day-usana BiopharmaWatch en 2026-10-01T11:07:00.000Z USANA CEO Kevin Guest Shares Three Ways to Celebrate International Music Day https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-meredith-manning-appointment BiopharmaWatch en 2026-10-01T11:05:00.000Z Unicycive Therapeutics Appoints Meredith Manning to Board of Directors https://www.biopharmawatch.com/news/HLF/herbalife-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-01T11:05:00.000Z Herbalife to Announce Third Quarter 2026 Results on November 2 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-sponsors-pediatric-orthopedic-course BiopharmaWatch en 2026-10-01T11:05:00.000Z OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course https://www.biopharmawatch.com/news/SGHT/sight-sciences-launch-omni-ultra-surgical-system-aao-2026 BiopharmaWatch en 2026-10-01T11:05:00.000Z Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting https://www.biopharmawatch.com/news/UNH/unitedhealthcare-2027-medicare-plans-affordability-simplicity BiopharmaWatch en 2026-10-01T11:00:00.000Z UnitedHealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience https://www.biopharmawatch.com/news/PODD/insulet-third-quarter-2026-financial-results-announcement BiopharmaWatch en 2026-10-01T11:00:00.000Z Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/NVCR/novocure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-01T11:00:00.000Z Novocure to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELV/elevance-health-2027-medicare-advantage-plans BiopharmaWatch en 2026-10-01T11:00:00.000Z Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support https://www.biopharmawatch.com/news/DHR/julie-sawyer-montgomery-ceo-danaher BiopharmaWatch en 2026-10-01T11:00:00.000Z Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer https://www.biopharmawatch.com/news/STTK/shattuck-labs-phase-2-trial-sl-325-hidradenitis-suppurativa BiopharmaWatch en 2026-10-01T11:00:00.000Z Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-update-fhd-909-strategic-priorities BiopharmaWatch en 2026-10-01T11:00:00.000Z Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities https://www.biopharmawatch.com/news/GLUE/monte-rosa-positive-results-mrt-8102-gforce-1-study BiopharmaWatch en 2026-10-01T11:00:00.000Z Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-october-conferences-2026 BiopharmaWatch en 2026-10-01T11:00:00.000Z Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences https://www.biopharmawatch.com/news/BSEM/biostem-strengthens-patent-portfolio BiopharmaWatch en 2026-10-01T11:00:00.000Z BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio https://www.biopharmawatch.com/news/GENB/roswell-park-generate-biomedicines-gb-5267-trial BiopharmaWatch en 2026-10-01T11:00:00.000Z Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer https://www.biopharmawatch.com/news/KYNB/kyntra-bio-appoints-andrew-singer-board-directors BiopharmaWatch en 2026-10-01T11:00:00.000Z Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors https://www.biopharmawatch.com/news/IOVA/iova-appoints-noah-berkowitz-cmo BiopharmaWatch en 2026-10-01T11:00:00.000Z Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer https://www.biopharmawatch.com/news/FATE/fate-therapeutics-fourth-quarter-2026-conferences BiopharmaWatch en 2026-10-01T11:00:00.000Z Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-champions-in-care-movement BiopharmaWatch en 2026-10-01T10:59:00.000Z Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement https://www.biopharmawatch.com/news/CAH/cardinal-health-extends-distribution-agreement-cvs-health BiopharmaWatch en 2026-10-01T10:50:00.000Z Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health https://www.biopharmawatch.com/news/MRK/merck-third-quarter-2026-conference-call BiopharmaWatch en 2026-10-01T10:45:00.000Z Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 https://www.biopharmawatch.com/news/CAH/cardinal-health-first-quarter-results-fy-2027 BiopharmaWatch en 2026-10-01T10:45:00.000Z Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5 https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-easd-2026-clinical-data BiopharmaWatch en 2026-10-01T10:45:00.000Z Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting https://www.biopharmawatch.com/news/AGMB/agomab-positive-topline-data-ontunisertib-crohns-disease BiopharmaWatch en 2026-10-01T10:30:08.000Z Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease https://www.biopharmawatch.com/news/AVTR/avantor-third-quarter-2026-earnings-report BiopharmaWatch en 2026-10-01T10:05:00.000Z Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/HIMS/hims-hers-appoints-chief-medical-officers-uk-australia BiopharmaWatch en 2026-10-01T10:00:00.000Z Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership https://www.biopharmawatch.com/news/KMTS/kestra-medical-five-star-rating-newsweek-2026 BiopharmaWatch en 2026-10-01T10:00:00.000Z Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies https://www.biopharmawatch.com/news/RDNT/radnet-win-nextgen-collaboration-medical-imaging BiopharmaWatch en 2026-10-01T10:00:00.000Z RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals https://www.biopharmawatch.com/news/TEVA/samsung-bioepis-teva-biosimilar-partnership-expansion BiopharmaWatch en 2026-10-01T08:30:00.000Z Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates https://www.biopharmawatch.com/news/STVN/ensera-launches-alliance-network-drug-device-combination-products BiopharmaWatch en 2026-10-01T08:00:00.000Z Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-10-01T07:16:38.266Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-10-01T07:16:06.247Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-october-2026 BiopharmaWatch en 2026-10-01T07:15:30.907Z FDA Calendar October 2026: Key PDUFA Dates and Insights https://www.biopharmawatch.com/news/PFE/pfizer-tilrekimig-phase-2-atopic-dermatitis-study BiopharmaWatch en 2026-10-01T06:30:00.000Z Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study https://www.biopharmawatch.com/news/OCS/oculis-national-ms-society-campaign-end-ms BiopharmaWatch en 2026-10-01T06:00:00.000Z Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-expand-alliance-next-generation-antibodies BiopharmaWatch en 2026-10-01T05:00:00.000Z Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies https://www.biopharmawatch.com/news/SNY/regeneron-sanofi-global-alliance-next-gen-antibodies BiopharmaWatch en 2026-10-01T05:00:00.000Z Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-30T23:12:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/UTHR/united-therapeutics-prevails-patent-litigation-liquidia BiopharmaWatch en 2026-09-30T23:09:00.000Z United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia https://www.biopharmawatch.com/news/RGT/royce-global-trust-performance-aug-2026 BiopharmaWatch en 2026-09-30T22:08:00.000Z Royce Global Trust (NYSE: RGT) as of Aug 31, 2026 https://www.biopharmawatch.com/news/PACS/pacs-post-acute-nursing-homes-2027 BiopharmaWatch en 2026-09-30T22:08:00.000Z Seventeen PACS Post-Acute Locations Named Top Nursing Homes for 2027 by Newsweek Magazine https://www.biopharmawatch.com/news/RMT/royce-micro-cap-trust-performance-august-2026 BiopharmaWatch en 2026-09-30T22:05:00.000Z Royce Micro-Cap Trust (NYSE: RMT) as of Aug 31, 2026 https://www.biopharmawatch.com/news/VIVI/tempramed-technologies-private-placement-closure BiopharmaWatch en 2026-09-30T22:00:00.000Z TempraMed Technologies Ltd. Announces Closing of Private Placement https://www.biopharmawatch.com/news/RVT/royce-small-cap-trust-performance-aug-2026 BiopharmaWatch en 2026-09-30T21:57:00.000Z Royce Small-Cap Trust (NYSE: RVT) as of Aug 31, 2026 https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-30T21:46:00.000Z Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BMY/fda-approves-expanded-indication-camzyos BiopharmaWatch en 2026-09-30T21:32:00.000Z U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-fpwr-symposium-2026 BiopharmaWatch en 2026-09-30T21:30:00.000Z Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference https://www.biopharmawatch.com/news/CLGN/collplant-reports-2026-q2-financial-results BiopharmaWatch en 2026-09-30T21:20:00.000Z COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE https://www.biopharmawatch.com/news/IMMX/immix-biopharma-closes-125-million-offering BiopharmaWatch en 2026-09-30T21:15:00.000Z Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock https://www.biopharmawatch.com/news/HCA/hca-healthcare-3q-2026-earnings-call BiopharmaWatch en 2026-09-30T21:03:00.000Z HCA Healthcare, Inc. 3rd Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/OCS/oculis-resignation-lionel-carnot-board BiopharmaWatch en 2026-09-30T20:46:00.000Z Oculis Announces Resignation of Lionel Carnot from Board of Directors https://www.biopharmawatch.com/news/LAB/standard-biotools-update-sale-mass-cytometry-business BiopharmaWatch en 2026-09-30T20:42:00.000Z Standard BioTools Provides Update on Sale of Mass Cytometry Business https://www.biopharmawatch.com/news/TEVA/tapi-names-serge-rogasik-ceo-growth-competitiveness BiopharmaWatch en 2026-09-30T20:32:00.000Z TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20260930 BiopharmaWatch en 2026-09-30T20:30:00.000Z Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CVS/cvs-health-declares-quarterly-dividend-20260930 BiopharmaWatch en 2026-09-30T20:26:00.000Z CVS Health declares quarterly dividend https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-david-raben-cmo BiopharmaWatch en 2026-09-30T20:10:00.000Z Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/INGN/inogen-divestiture-us-oxygen-rental-business BiopharmaWatch en 2026-09-30T20:05:00.000Z Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech https://www.biopharmawatch.com/news/CRVS/corvus-phase-1b-soquelitinib-hidradenitis-suppurativa BiopharmaWatch en 2026-09-30T20:05:00.000Z Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa https://www.biopharmawatch.com/news/SCNX/scienture-holdings-reverse-stock-split BiopharmaWatch en 2026-09-30T20:05:00.000Z Scienture Holdings, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-operational-highlights-h1-2026-results BiopharmaWatch en 2026-09-30T20:05:00.000Z RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-appoints-jim-daly-board-directors BiopharmaWatch en 2026-09-30T20:05:00.000Z Halozyme Announces Appointment of Jim Daly to its Board of Directors https://www.biopharmawatch.com/news/LGVN/longeveron-participate-longevity-investment-conferences BiopharmaWatch en 2026-09-30T20:05:00.000Z Longeveron to Participate in Three Longevity/Aging Investment Conferences https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ueg-week-2026 BiopharmaWatch en 2026-09-30T20:05:00.000Z Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 https://www.biopharmawatch.com/news/LTRN/lantern-pharma-inc-announces-closing-8-million-registered-direct-offering BiopharmaWatch en 2026-09-30T20:01:00.000Z Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering https://www.biopharmawatch.com/news/GLUE/monte-rosa-mrt-8102-gforce-1-phase-1-results BiopharmaWatch en 2026-09-30T20:01:00.000Z Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk https://www.biopharmawatch.com/news/HIT/health-in-tech-launches-hitrx-modernize-health-insurance BiopharmaWatch en 2026-09-30T20:00:00.000Z Health In Tech Launches HitRix to Modernize the Nearly $1 Trillion U.S. Self-Funded Health Insurance Market and Announces Updated 2026 Full-Year Revenue Guidance https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-ai-humanoid-nursing-robots BiopharmaWatch en 2026-09-30T18:00:00.000Z Healthcare Triangle, Inc Signs MOU to Bring AI-Enabled Humanoid Nursing Robots to Hospitals in North America https://www.biopharmawatch.com/news/HSDT/solana-company-announces-15-million-offering BiopharmaWatch en 2026-09-30T17:57:00.000Z Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor https://www.biopharmawatch.com/news/LQDA/liquidia-update-hatch-waxman-litigation-patent-327 BiopharmaWatch en 2026-09-30T17:20:00.000Z Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent https://www.biopharmawatch.com/news/RVP/retractable-technologies-declares-dividends-preferred-stock BiopharmaWatch en 2026-09-30T17:17:00.000Z Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders https://www.biopharmawatch.com/news/CELU/celularity-fontaine-vitale-opening-2027 BiopharmaWatch en 2026-09-30T15:57:00.000Z Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner https://www.biopharmawatch.com/news/NKTR/biomarker-data-rezpegaldesleukin-atopic-dermatitis BiopharmaWatch en 2026-09-30T14:30:00.000Z New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis https://www.biopharmawatch.com/news/QTTB/q32-bio-signal-aa-trial-results-2026 BiopharmaWatch en 2026-09-30T13:15:00.000Z Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 https://www.biopharmawatch.com/news/SLGL/sol-gel-kol-investor-day-sgt-610-october-2026 BiopharmaWatch en 2026-09-30T13:14:00.000Z Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 https://www.biopharmawatch.com/news/AGL/agilon-health-jackson-clinic-partnership-aco BiopharmaWatch en 2026-09-30T13:00:00.000Z agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO https://www.biopharmawatch.com/news/BAX/baxter-connected-hospital-report-2026 BiopharmaWatch en 2026-09-30T13:00:00.000Z Baxter Releases Inaugural Connected Hospital Report https://www.biopharmawatch.com/news/DGX/ecg-screening-program-florida-high-school-athletes BiopharmaWatch en 2026-09-30T13:00:00.000Z Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes https://www.biopharmawatch.com/news/IDXX/idexx-acquires-covetai-chicago-pacific-founders-exit BiopharmaWatch en 2026-09-30T13:00:00.000Z Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-earnings-call-2026 BiopharmaWatch en 2026-09-30T13:00:00.000Z Abbott hosts conference call for third-quarter earnings https://www.biopharmawatch.com/news/MDT/medtronic-regulatory-milestones-cardiac-mapping-software BiopharmaWatch en 2026-09-30T13:00:00.000Z Medtronic announces regulatory milestones for newest cardiac mapping and ablation software https://www.biopharmawatch.com/news/HQY/healthequity-appoints-noemie-heuland-board-directors BiopharmaWatch en 2026-09-30T13:00:00.000Z HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors https://www.biopharmawatch.com/news/HYPD/hyperion-defi-launches-institutional-credit-facility BiopharmaWatch en 2026-09-30T13:00:00.000Z Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid https://www.biopharmawatch.com/news/ONMD/onemednet-signs-seven-figure-agreement-ai-data-solution BiopharmaWatch en 2026-09-30T12:55:00.000Z OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution https://www.biopharmawatch.com/news/SILO/silo-pharma-qwikagents-ai-platform-expansion BiopharmaWatch en 2026-09-30T12:50:00.000Z Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-therapy BiopharmaWatch en 2026-09-30T12:44:00.000Z AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-mass-general-brigham-clinical-trial BiopharmaWatch en 2026-09-30T12:32:00.000Z Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-safety-results-ind-studies BiopharmaWatch en 2026-09-30T12:32:00.000Z Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND https://www.biopharmawatch.com/news/LNTH/lantheus-cms-grants-pylarity-truvu-status BiopharmaWatch en 2026-09-30T12:30:00.000Z Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18) https://www.biopharmawatch.com/news/DMAC/diamedica-kol-webinar-dm199-fgr-results BiopharmaWatch en 2026-09-30T12:30:00.000Z DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results https://www.biopharmawatch.com/news/SRPT/sarepta-elevidys-data-world-muscle-society-2026 BiopharmaWatch en 2026-09-30T12:30:00.000Z Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne https://www.biopharmawatch.com/news/NBIX/neurocrine-research-prader-willi-syndrome-vykat-xr BiopharmaWatch en 2026-09-30T12:30:00.000Z Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference https://www.biopharmawatch.com/news/LH/labcorp-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-30T12:30:00.000Z Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-small-cap-showcase-presentation BiopharmaWatch en 2026-09-30T12:30:00.000Z Decoy Therapeutics to Present at The Small Cap Showcase https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-integrated-clinical-biomarker-data-showed-durable-local BiopharmaWatch en 2026-09-30T12:30:00.000Z Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer https://www.biopharmawatch.com/news/MRK/merck-tulisokibart-phase-2b-hidradenitis-suppurativa BiopharmaWatch en 2026-09-30T12:15:00.000Z Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-tabelecleucel-bla-resubmission BiopharmaWatch en 2026-09-30T12:05:00.000Z Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-prostate-cancer-astro-2026 BiopharmaWatch en 2026-09-30T12:05:00.000Z Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 https://www.biopharmawatch.com/news/ARDX/ardelyx-honors-pm360-trailblazer-awards-2026 BiopharmaWatch en 2026-09-30T12:01:00.000Z Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards https://www.biopharmawatch.com/news/NCNA/nucana-grant-patent-nuc-7738-europe BiopharmaWatch en 2026-09-30T12:00:57.000Z NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe https://www.biopharmawatch.com/news/BIAF/bioaffinity-avmedical-partnership-cypath-lung-cancer-test BiopharmaWatch en 2026-09-30T12:00:00.000Z bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL https://www.biopharmawatch.com/news/KARD/kardigan-appoints-kristin-reinke-board-directors BiopharmaWatch en 2026-09-30T12:00:00.000Z Kardigan Announces Appointment of Kristin Reinke to its Board of Directors https://www.biopharmawatch.com/news/CELC/celcuity-revtorpyk-commercial-availability BiopharmaWatch en 2026-09-30T12:00:00.000Z Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-feedback-abp-450-biosimilar-development BiopharmaWatch en 2026-09-30T12:00:00.000Z AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-01-virage-phase-2b-results BiopharmaWatch en 2026-09-30T12:00:00.000Z Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine https://www.biopharmawatch.com/news/BSEM/biostem-technologies-3-million-private-placement BiopharmaWatch en 2026-09-30T12:00:00.000Z BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-ycanthe-data-dermatology-conferences BiopharmaWatch en 2026-09-30T12:00:00.000Z Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences https://www.biopharmawatch.com/news/IMMP/immutep-receives-rd-tax-incentive BiopharmaWatch en 2026-09-30T12:00:00.000Z Immutep Receives ~A$0.86 Million R&D Tax Incentive https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-data-eprx BiopharmaWatch en 2026-09-30T12:00:00.000Z Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-announces-first-patient-successfully-dosed-phase-2-3 BiopharmaWatch en 2026-09-30T12:00:00.000Z Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/PMN/upcoming-conferences-events-october-2026 BiopharmaWatch en 2026-09-30T12:00:00.000Z Upcoming Conferences and Events in October https://www.biopharmawatch.com/news/INKT/mink-therapeutics-arpa-h-room-temperature-cell-therapy BiopharmaWatch en 2026-09-30T11:57:00.000Z MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy https://www.biopharmawatch.com/news/IMNM/immunome-ind-clearance-im-1340-antibody-drug-conjugate BiopharmaWatch en 2026-09-30T11:45:00.000Z Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors https://www.biopharmawatch.com/news/ABUS/arbutus-preliminary-results-tender-offer BiopharmaWatch en 2026-09-30T11:30:00.000Z Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/CYTK/cytokinetics-launches-aspen-hcm-study-myorzo BiopharmaWatch en 2026-09-30T11:30:00.000Z Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/CNSY/cerenome-cnside-third-quarter-update BiopharmaWatch en 2026-09-30T11:30:00.000Z Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings https://www.biopharmawatch.com/news/WVE/gsk-selects-waves-sirna-program-for-development BiopharmaWatch en 2026-09-30T11:30:00.000Z Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development https://www.biopharmawatch.com/news/EVGN/evogene-nasdaq-grants-180-day-compliance-period BiopharmaWatch en 2026-09-30T11:15:00.000Z Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance https://www.biopharmawatch.com/news/OCGN/ocugen-participate-scientific-conferences BiopharmaWatch en 2026-09-30T11:02:00.000Z Ocugen to Participate in Upcoming Scientific Conferences https://www.biopharmawatch.com/news/MSLE/satellos-completes-enrollment-basecamp-phase-2-trial BiopharmaWatch en 2026-09-30T11:00:00.000Z Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy https://www.biopharmawatch.com/news/CTSO/cytosorbents-new-data-presentations-conferences BiopharmaWatch en 2026-09-30T11:00:00.000Z CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-orphan-drug-designation-intranasal-foralumab BiopharmaWatch en 2026-09-30T11:00:00.000Z Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) https://www.biopharmawatch.com/news/NRXP/nrx-defense-systems-darpa-contract-evaluate-robotic-tms BiopharmaWatch en 2026-09-30T11:00:00.000Z NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression https://www.biopharmawatch.com/news/CBLL/ceribell-fda-clearance-eeg-software BiopharmaWatch en 2026-09-30T11:00:00.000Z Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis https://www.biopharmawatch.com/news/HROW/harrow-ophthalmic-portfolio-aaopt-aao-2026 BiopharmaWatch en 2026-09-30T11:00:00.000Z Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO https://www.biopharmawatch.com/news/JBIO/jade-biosciences-preclinical-data-jade301-dermatomyositis BiopharmaWatch en 2026-09-30T11:00:00.000Z Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-kainetic-phase-3-enrollment-completed BiopharmaWatch en 2026-09-30T11:00:00.000Z Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-preliminary-topline-data-global-phase-2 BiopharmaWatch en 2026-09-30T11:00:00.000Z Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation https://www.biopharmawatch.com/news/ANL/adlai-nortye-appoints-christopher-liu-head-investor-relations BiopharmaWatch en 2026-09-30T11:00:00.000Z Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fluocinolone-acetonide-data-aao-2026 BiopharmaWatch en 2026-09-30T10:55:00.000Z ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting https://www.biopharmawatch.com/news/HSIC/henry-schein-cares-25-years-health-happen BiopharmaWatch en 2026-09-30T10:30:00.000Z Henry Schein Cares Marks 25 Years of Helping Health Happen® https://www.biopharmawatch.com/news/CMPS/compass-pathways-appoints-kelley-boucher-cpo BiopharmaWatch en 2026-09-30T10:30:00.000Z Compass Pathways Appoints Kelley Boucher as Chief People Officer https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-offering-115-million BiopharmaWatch en 2026-09-30T10:19:00.000Z Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/SGMT/sagimet-positive-results-denifanstat-acne-trial BiopharmaWatch en 2026-09-30T10:00:00.000Z Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-phase-1-data-abbv-295-easd-2026 BiopharmaWatch en 2026-09-30T09:45:00.000Z AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 https://www.biopharmawatch.com/news/VBIO/valion-bio-shear-kershman-entolimod-formulation BiopharmaWatch en 2026-09-30T07:45:00.000Z Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity https://www.biopharmawatch.com/news/MRNA/moderna-coo-role-expansion-oncology BiopharmaWatch en 2026-09-30T07:00:00.000Z Moderna Adds Chief Operating Officer Role as Company Expands into Oncology https://www.biopharmawatch.com/news/ABBV/abbvie-phase-2-apex-study-zumilokibart-results BiopharmaWatch en 2026-09-30T05:30:00.000Z AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-public-offering-pricing BiopharmaWatch en 2026-09-30T05:11:00.000Z Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering https://www.biopharmawatch.com/news/TAK/zasocitinib-efficacy-deucravacitinib-phase-3-results BiopharmaWatch en 2026-09-30T05:00:00.000Z Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill https://www.biopharmawatch.com/news/ABBV/abbvie-dermatology-research-eadv-congress-2026 BiopharmaWatch en 2026-09-30T05:00:00.000Z AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress https://www.biopharmawatch.com/news/VCRE/increase-in-shares-and-votes-vicore-pharma BiopharmaWatch en 2026-09-30T03:20:00.000Z Increase in Number of Shares and Votes in Vicore Pharma https://www.biopharmawatch.com/news/LLY/ebglyss-phase-3b-results-atopic-dermatitis BiopharmaWatch en 2026-09-30T00:00:00.000Z New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA... https://www.biopharmawatch.com/news/LLY/lilly-elora-tzp-phase-2b-results BiopharmaWatch en 2026-09-30T00:00:00.000Z Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b... https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-positive-phase-iii-results-hetlioz BiopharmaWatch en 2026-09-29T22:45:00.000Z Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder https://www.biopharmawatch.com/news/DBVT/dbv-technologies-submission-biologics-license-application BiopharmaWatch en 2026-09-29T22:29:00.000Z DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years